Openbookopenbook
Equity
Eledon Pharmaceuticals Inc(ELDN)
USD --+0.00%
Reward40Moderate
Risk52Moderate
📊75%Data
ELDN
+0.0 · +0.00%
USD · NASDAQ
Eledon Pharmaceuticals Inc | Healthcare
Value Trap
Market Cap:195.09M
ℹ️
Reward Rating
40
Moderate
Bottom 10% (model universe)
75% data coverage
ℹ️
Risk Rating
52
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ELDN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $8.00.

What is Eledon Pharmaceuticals Inc?

operates as a clinical stage biotechnology company.

ELDN · Verdict

Moderate reward · elevated risk

ELDN stands out on balance sheet and valuation, but watch the cash flow signal.

Based on 88% data coverage

ELDN · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet86/100

    Current ratio 12.42

  • Valuation84/100

    P/E 5.4×

Watchouts 3

  • Cash flow5/100

    Weak vs peers

  • Profitability10/100

    -95% return on equity

  • Growth31/100

    Earnings +1.6% CAGR

Model-based scoring. For information only — not financial advice.

What is Eledon Pharmaceuticals Inc?

operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 195.09M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap195.09M
P/E RatioN/A
Dividend YieldN/A
52 Week High4.6
52 Week Low1.35
Last AnnualDecember
IPO Date9/17/2014
IncorporatedUSA
Shares Outstanding80M
No. of Employees31
IndustryBiotechnology
ExchangeNASDAQ
Beta0.893
CurrencyUSD
Websiteeledon.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.